Charlottesville, VA – According to filings with the U.S. Securities and Exchange Commission, Adial Pharmaceuticals is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Stilley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Adial Pharmaceuticals
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of addictions. The Companys lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Companys proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

To learn more about Adial Pharmaceuticals, visit http://www.adialpharma.com/

Contact:
William Stilley, Chief Executive Officer
434-422-9800
wstilley@adialpharma.com
https://www.linkedin.com/in/williamstilley/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved